The Pathological Response to Anthracycline is Associated with Topoisomerase IIα Gene Amplification in the HER2 Breast Cancer Subset.

Journal of surgery and science Pub Date : 2014-12-01

Takashi Ishikawa, Takeshi Sasaki, Mikiko Tanabe, Kazutaka Narui, Kumiko Kida, Kazuhiro Shimada, Daisuke Shimizu, Akimitsu Yamada, Satoshi Morita, Mari S Oba, Kae Kawachi, Akinori Nozawa, Yasushi Ichikawa, Kazuaki Takabe, Itaru Endo

{"title":"The Pathological Response to Anthracycline is Associated with Topoisomerase IIα Gene Amplification in the HER2 Breast Cancer Subset.","authors":"Takashi Ishikawa, Takeshi Sasaki, Mikiko Tanabe, Kazutaka Narui, Kumiko Kida, Kazuhiro Shimada, Daisuke Shimizu, Akimitsu Yamada, Satoshi Morita, Mari S Oba, Kae Kawachi, Akinori Nozawa, Yasushi Ichikawa, Kazuaki Takabe, Itaru Endo","doi":"","DOIUrl":null,"url":null,"abstract":"Background: HER2-positive breast cancer sensitivity to anthracyclines is enhanced when topoisomerase IIα (TOP2A) is co-amplified under both adjuvant and metastatic settings. However, the relationship between anthracycline sensitivity and TOP2A amplification in HER2-positive breast cancers in neoadjuvant settings is not known.Methods: The TOP2A gene status was examined by FISH in biopsies from 18 patients who received anthracycline and cyclophosphamide before surgery.Results: The TOP2A gene was amplified in 6/17 patients and was significantly associated with pathological response to the chemotherapy regimen.Conclusions: TOP2A amplification could predict anthracycline-sensitivity. Thus, the HER2/TOP2A co-amplified subtype may be effectively treated by anthracycline-containing regimens alone.","PeriodicalId":90243,"journal":{"name":"Journal of surgery and science","volume":"2 1","pages":"10-12"},"PeriodicalIF":0.0000,"publicationDate":"2014-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4309011/pdf/nihms656984.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of surgery and science","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background: HER2-positive breast cancer sensitivity to anthracyclines is enhanced when topoisomerase IIα (TOP2A) is co-amplified under both adjuvant and metastatic settings. However, the relationship between anthracycline sensitivity and TOP2A amplification in HER2-positive breast cancers in neoadjuvant settings is not known.

Methods: The TOP2A gene status was examined by FISH in biopsies from 18 patients who received anthracycline and cyclophosphamide before surgery.

Results: The TOP2A gene was amplified in 6/17 patients and was significantly associated with pathological response to the chemotherapy regimen.

Conclusions: TOP2A amplification could predict anthracycline-sensitivity. Thus, the HER2/TOP2A co-amplified subtype may be effectively treated by anthracycline-containing regimens alone.

Abstract Image

本刊更多论文

HER2乳腺癌亚群对蒽环类药物的病理反应与拓扑异构酶i α基因扩增相关

背景:her2阳性乳腺癌对蒽环类药物的敏感性增强，当拓扑异构酶i α (TOP2A)在辅助和转移情况下共同扩增时。然而，在her2阳性乳腺癌的新辅助治疗中，蒽环类药物敏感性与TOP2A扩增之间的关系尚不清楚。方法:对术前接受蒽环类药物和环磷酰胺治疗的18例患者的活检组织进行TOP2A基因状态的FISH检测。结果:6/17例患者中TOP2A基因扩增，与化疗方案的病理反应显著相关。结论:TOP2A扩增可预测蒽环类药物敏感性。因此，HER2/TOP2A共扩增亚型可以单独使用含蒽环类药物有效治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of surgery and science

自引率

0.00%

发文量